Interested in new trials?
Get alerts for new trials in your area by subscribing now
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
What is schizophrenia?
Schizophrenia is a chronic brain disorder that changes how a person thinks, perceives, and relates to reality. Its symptoms fall into three groups. Positive symptoms are experiences added to normal life: hallucinations, most often hearing voices, and delusions, fixed beliefs not shared by others. Negative symptoms are things taken away: motivation, emotional expression, speech, and pleasure. Cognitive symptoms affect attention, memory, and planning. The word means "split mind," coined in 1908 to describe a fragmenting of mental functions, and it has nothing to do with having multiple personalities. Symptoms usually emerge between the late teens and early thirties, often after a gradual decline in functioning, and slightly earlier in men than women. It affects a little under 1 percent of people, with estimates for the US ranging from about 0.25 to 0.64 percent of adults.
The causes are a mix of genetics and environment. Heritability is high, and having a parent with schizophrenia raises risk to roughly 1 in 10, but most people with the disorder have no affected relative, and most relatives never develop it. Complications around birth, childhood adversity, living in cities, and heavy cannabis use in adolescence, especially of high potency products, are among the environmental factors linked to higher risk in people already vulnerable. Treatment combines antipsychotic medicine with psychosocial support, and most people improve, though negative and cognitive symptoms often persist and about a third of people respond poorly to standard drugs. That is the gap research targets: medicines that work through new brain systems, treatments for negative and cognitive symptoms, and add on drugs for people whose illness resists standard care. It is not the same as bipolar disorder, although psychotic symptoms can appear in both.
What is new in schizophrenia treatment
Cobenfy works by activating muscarinic receptors, part of the brain's acetylcholine system, rather than blocking dopamine. In its trials it reduced symptoms without weight gain, sedation, or movement disorders, the side effects that lead many people to stop older medicines. A second muscarinic drug, emraclidine, is in trials, and evenamide, which acts on glutamate release, is in Phase 3 as an add on for people whose symptoms persist despite standard treatment. Other studies test long acting formulations, anti inflammatory approaches, and ways to predict who will respond to clozapine, the most effective drug for resistant illness and the most underused. Most of these approaches exist only inside trials today.
Types of schizophrenia clinical trials
New mechanism medicines. Muscarinic agonists and glutamate modulators tested against placebo, usually in people with a recent worsening of symptoms.
Add on trials for resistant illness. New drugs added to a stable antipsychotic in people whose symptoms continue, including Phase 3 studies.
Switching and real world studies. Large studies of what happens when people move from an older antipsychotic to a newer one, measuring benefits and side effects in everyday practice.
Long term safety studies. Year long open label trials that track a new medicine over time.
Brain and biology research. Imaging, genetics, and studies of inflammation or cannabis exposure that aim to explain the illness and find markers of treatment response, often enrolling healthy comparison volunteers too.
Psychosocial and cognitive studies. Cognitive training, brain stimulation for cognition, and programs for early psychosis.
What causes schizophrenia?
A combination of genetic vulnerability and environmental factors, including complications around birth, childhood adversity, urban upbringing, and heavy adolescent cannabis use. Changes in dopamine and glutamate signaling in the brain are involved, which is why new medicines target those systems.
Who can participate in schizophrenia clinical trials?
Most medicine trials enroll adults 18 to 65 with a confirmed diagnosis, often of several years, and specify the current state: an acute worsening for placebo controlled trials of new drugs, or stable symptoms on a steady antipsychotic dose for add on and switching studies. Trials for resistant schizophrenia require documented lack of response to at least two prior antipsychotics. Most exclude active substance use disorders and recent suicidal behavior, and many require a stable living situation and a person who can help with visits. Research studies of brain biology often accept people at any stage and healthy volunteers for comparison. Consent must be given by the participant, and study teams assess understanding carefully. Eligibility always varies by study.
New to research? Read how informed consent works, including how capacity to consent is assessed.
Stages of schizophrenia, and why they matter for trials
Clinical high risk or prodrome. Early, milder changes in thinking and perception before a first episode. Studied in prevention and early intervention trials, mostly in teenagers and young adults.
First episode psychosis. The first full episode, usually in the late teens or twenties. Early treatment programs and some medicine trials focus here.
Established schizophrenia, acute. A relapse or worsening of positive symptoms. The usual setting for placebo controlled trials of new medicines, often with a short hospital stay.
Established, stable. Symptoms controlled on medicine. The setting for add on, switching, cognitive, and long term safety studies.
Treatment resistant. Inadequate response to two or more antipsychotics. The target of clozapine research and new add on drugs.
Study titles use exactly these words, and they decide which studies fit better than any other detail.
How to enroll in a schizophrenia clinical trial
Identify your trial. Use the filters. Titles state the illness stage and whether the study is a new medicine, an add on, a switch, or research.
Select your preferred location. Enter your city or state. Medicine trials run at psychiatric research centers and often include weekly visits; some acute trials include an inpatient stay.
Explore study details. Click "Learn More" for the required stage, current medicine rules, and whether a support person is needed.
Complete the health profile. Click "Get started" to begin the 5-step application. Have three things ready: your diagnosis and how long ago it was made, the antipsychotics you have tried and how you responded, and your current medicines. A family member or care partner can help complete the application.
Submit the application. A clinical trial coordinator reviews it and contacts you. Nothing is decided until informed consent, and participation is voluntary at every step. Trials are not a substitute for care in a crisis, and study teams will refer you to help if you need it now.